Endothelial dysfunction is considered critical in the initiation, progression, and complications of coronary artery disease and is independently associated with cardiovascular events. It is a reversible process that represents the functional expression of an individual's overall cardiovascular risk factor burden, and many therapies that restore endothelial function also decrease cardiovascular events. Coronary endothelial function is regulated by the balance of endothelium-derived vasodilator and vasoconstrictor factors such as endothelin-1. This study provides evidence that long-term ET A receptor antagonist administration improves coronary microvascular endothelial function in humans and supports a role for endogenous endothelin in the mechanism and potentially the treatment of coronary endothelial function in humans. See p 958.
Homoarginine, Cardiovascular Risk, and Mortality
Evidence suggests that homoarginine, a cationic acid formed from lysine, may impact nitric oxide metabolism, endothelial function, and insulin secretion, all of which are relevant for the maintenance of cardiovascular health. In the present study, the association of circulating homoarginine concentrations with cardiovascular outcomes and with mortality was assessed in 2 separate large cohorts: 3305 subjects referred for coronary angiography (LUdwigshafen RIsk and Cardiovascular Health [LURIC] study) and 1244 diabetic patients undergoing maintenance hemodialysis (Die Deutsche Diabetes Dialyse Studie [4D] study). Low blood homoarginine concentration was strongly associated with death in both cohorts. In the LURIC population, persons with values of blood homoarginine in the lowest quartile had a more than 3-fold higher cardiovascular mortality than those with levels in the highest quartile after adjustment for other known vascular risk factors. Circulating homoargin-ine levels were markedly lower in hemodialysis patients (4D population), who overall had a 5-fold greater mortality than patients referred for coronary angiography. In the dialysis patients, a similar association between lower homoarginine quartiles and greater mortality was seen. With the 2 independent cohorts, which evaluated a diverse spectrum of patients, the present study demonstrates a consistent, strong association of homoarginine with cardiovascular and all-cause mortality and suggests important new avenues for future research. See p 967.
Independent Susceptibility Markers for Atrial Fibrillation on Chromosome 4q25
Atrial fibrillation (AF) is a heritable disorder with evidence of genetic susceptibility. Common single-nucleotide polymorphisms (SNPs) in a noncoding region on chromosome 4q25 have been associated with AF. We sought to determine whether more than 1 AF susceptibility signal exists at this locus. We genotyped SNPs at the chromosome 4q25 locus in 790 case subjects and 1177 control subjects. After adjustment for the genotype of the most significantly associated SNP, the SNPs that remained significantly associated with AF were replicated in an additional 5066 subjects with AF and 30 661 without AF. We identified 3 distinct AF susceptibility signals, 2 of which have not been described previously. A multimarker risk score composed of SNPs tagging each of these 3 AF susceptibility signals identified individuals at varying risk of developing AF. Among the 1% of subjects homozygous for AF risk alleles at SNPs tagging each susceptibility signal, the risk of AF was markedly increased relative to those with the most common genotypes at these SNPs (relative risk 6.02, 95% confidence interval 4.56 to 7.96, Pϭ1.2ϫ10 Ϫ36 ). Consideration of multiple susceptibility signals at the chromosome 4q25 locus identifies individuals with a markedly increased risk of AF and may facilitate the localization of regulatory elements at this locus with particular biological relevance in the pathogenesis of AF. See p 976.
Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy
Cardiac resynchronization therapy has been shown to reduce the risk of death or heart failure in patients with class III or IV heart failure. The Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy (MADIT-CRT) study extended these results to patients with class I and II heart failure. In this echocardiographic substudy of MADIT-CRT, we observed substantial improvement in cardiac size and function in patients who received combined therapy with cardiac resynchronization and an implantable cardioverter defibrillator versus those receiving implantable cardioverter defibrillator therapy only. We observed reductions in end-diastolic volume, end-systolic volume, and left atrial volume and improvement in left ventricular ejection fraction and right ventricular fractional area change. These findings were concordant with the improvement in outcomes, and outcomes after 1 year were directly related to the extent of improvement in ventricular size and function between baseline and 1 year. These data provide a direct link between the improvement in cardiac size and function with CRT and improvement in outcomes. See p 985.
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Differential Cardiac Remodeling in Preload Versus Afterload
Hemodynamic load regulates myocardial function and gene expression. Increased load triggers molecular, structural, and functional remodeling and eventually heart failure. Increased left ventricular load acts either as preload because of left to right shunt or aortic or mitral regurgitation or as increased afterload because of aortic stenosis or arterial hypertension. In the present study, different cardiac gene expression, signaling, and remodeling with preload or afterload were studied in mice with aortocaval shunt (preload) or transverse aortic constriction (afterload) with matched mean total wall stresses. Here we show that increased afterload results in maladaptive hypertrophy with increased fibrosis, inflammation, cardiomyocyte apoptosis, development of heart failure, and increased mortality. Increased preload results in a more favorable type of hypertrophy without increased fibrosis and inflammation and with less apoptosis and better survival. Ventricular brain natriuretic peptide expression is increased only with afterload but not with preload. Gene expression and signaling pathways differ considerably with preload and afterload. Calcium/calmodulin-dependent protein kinase II␦-mediated signaling may be the dominant maladaptive pathway in pressure overload, whereas activation of the Akt pathway may be dominant in volume overload. The data indicate that differential therapeutic strategies should be developed to address the specific signaling pathways activated with preload versus afterload. This may prevent or delay the development of heart failure in patients with increased preload or afterload, respectively. See p 993.
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Heart failure represents an enormous medical and societal burden. In the past, hypertension and valvular heart disease were the primary causes of heart failure in the United States. In recent years, however, coronary artery disease has emerged as the major cause of heart failure (ischemic cardiomyopathy). Notably, the degree of left ventricular dysfunction in ischemic cardiomyopathy is often out of proportion to the amount of overtly infarcted heart tissue. This suggests that ischemia per se can cause cardiac dysfunction. The Prolyl Hydroxylase Domain-Containing Protein (PHD) prolyl hydroxylases translate changes in oxygen bioavailability into changes in the abundance of the hypoxia-inducible factor transcriptional factor, a master regulator of cellular response to hypoxia. Under low oxygen conditions, such as occurs during ischemia, PHD function is impaired and hypoxia-inducible factor becomes active. Here, we show that genetically ablating PHD activity in the hearts of mice causes ultrastructural, histological, and functional changes reminiscent of ischemic cardiomyopathy. We show that long-term expression of a constitutively active hypoxia-inducible factor variant also leads to cardiomyopathy. Additionally, we document hypoxia-inducible factor upregulation in a murine chronic myocardial ischemia model and in autopsy samples from patients with ischemic cardiomyopathy. Collectively, our data suggest that long-term PHD inactivation and subsequent long-term hypoxia-inducible factor activation contribute to the pathogenesis of ischemic cardiomyopathy. See p 1004.
Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation
All guidelines agree on the need for at least 1 year of doubleantiplatelet therapy after drug-eluting stent implantation. Our study, conducted in 29 hospitals, shows that 14.4% of 1622 patients receiving drug-eluting stents interrupted at least 1 antiplatelet drug for at least 5 consecutive days during the first year after implantation. Although antiplatelet therapy discontinuation (ATD) can be justified by the occurrence of major hemorrhage or surgical procedure, these events occurred in only 25.7% of ATD cases. The most common scenarios for ATD were minor hemorrhages/procedures, medical decisions without any bleeding or bleeding-risk event, and patient initiative. Several patient characteristics predicted higher risk for ATD; some were associated with future bleeding events or the need for invasive procedures, whereas others were associated with ATD due to patient initiative. Although these determinants are not modifiable, they emphasize the need for careful patient selection. Other determinants were related to the process of care. Thus, long-term use of anticoagulants predicted ATD due to medical decision, whereas simple provision of written instructions about the importance of antiplatelet maintenance may avoid some cases of unjustified ATD. These results highlight that medical patterns of care of patients with drug-eluting stents should be better defined, particularly relative to the maintenance of antiplatelet therapy during procedures. In addition, they illustrate a common dilemma in contemporary medicine as a whole, not just in cardiology: Patients who are cared for by their general practitioners may pose formidable dilemmas to such practitioners because of the subtleties of the therapeutic technology used by different specialists. See p 1017.
C5a Receptor Targeting in Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice
Despite the success of antiproliferative therapies, restenosis remains a common problem after vascular intervention. The receptor for complement C5a (C5aR) has been identified in human atherosclerotic tissue, and adverse cardiovascular events have been correlated with C5a plasma levels. Receptor binding of C5a leads to proinflammatory activation of many cell types, but the role of receptormediated action during arterial remodeling after injury has not been studied. In the present study, we examined the contribution of the C5aR to neointima formation in apolipoprotein E-deficient mice employing a human peptidomimetic C5aR antagonist and a C5aRblocking monoclonal antibody. Our results indicate a strong protective effect by short-term (1 week) blockade of C5aR with C5aR antagonist or anti-C5aR monoclonal antibody on neointimal plaque formation, leukocyte recruitment, and vascular cell adhesion molecule-1 expression. In contrast, long-term treatment (3 weeks) reduced inflammatory cell recruitment and vascular cell adhesion molecule-1 expression but also induced plasminogen activator inhibitor-1-dependent smooth muscle cell migration to the neointima, thus stabilizing but not reducing plaques. Further studies confirmed that protective effects of short-term C5aR antagonist treatment persisted over 3 weeks after injury. On the basis of these properties, C5aR targeting can be considered an attractive pharmacological strategy for short-term treatment of vascular injury and inflammation. However, long-term approaches should account for direct or indirect effects of C5aR signaling on adaptive immune responses, cell apoptosis, migration, and tissue regeneration or fibrosis that may affect such treatment. Thus, our study provides the first evidence that intervention of the complement cascade at the level of C5aR may be clinically feasible to limit restenosis after vascular injury. See p 1026.
